European equities traded in the US as American depositary receipts were moving lower late Tuesday morning, declining 0.37% to 1,317.16 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies (DBVT) and Cellectis (CLLS), which climbed 14% and 4.6% respectively. They were followed by furniture maker Natuzzi (NTZ) and pharmaceutical company Novo Nordisk (NVO), which rose 4.1% and 1.8% respectively.
The decliners from continental Europe were led by biopharmaceutical company Genfit (GNFT) and financial services company Banco Bilbao Vizcaya Argentaria (BBVA), which fell 8.4% and 2.6% respectively. They were followed by petroleum refiner Equinor (EQNR) and medical device maker EDAP TMS (EDAP), which lost 2% each.
From the UK and Ireland, the gainers were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company NuCana (NCNA), which increased 6% each. They were followed by biotech firm Autolus Therapeutics (AUTL) and cruise line operator Carnival (CUK), which were up 4.7% and 1.7% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical companies Akari Therapeutics (AKTX) and TC Biopharm (TCBP), which fell 10% and 5.9% respectively. They were followed by biopharmaceutical companies Adaptimmune Therapeutics (ADAP) and Amarin (AMRN), which were down 4.8% and 2.5% respectively.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。